GHK-Cu is not a controlled substance in the UK and can be legally supplied for laboratory research purposes only
Clinical trials with GLP-1 receptor agonists consistently demonstrate significant weight loss, with higher doses (such as semaglutide 2.4 mg weekly) producing approximately 15% average weight loss in adults without diabetes in clinical trials (somewhat less in type 2 diabetes) when combined with lifestyle modification
medical professionals can administer IV fluids, electrolyte replacement, and anti-nausea medications to prevent organ damage
Under no circumstances should it be utilised as a drug, agricultural or pesticide product, food additive, or household chemical
When you lose weight, the fat cells become smaller and when you gain weight, they become bigger
As someone who's struggled with overeating, this supplement has significantly curbed my appetite without any side effects